KUALA LUMPUR, Feb 23 (Bernama) — Public-listed healthcare company, Malaysian Genomics Resource Centre Berhad (MGRC), and its subsidiary, pathology services company Clinipath (Malaysia) Sdn Bhd (Clinipath) today announced the availability of Dtect BRCA+, an affordable genetic screening test that examines key genes associated with hereditary breast and ovarian cancers.
Breast and ovarian cancers are two of the most common cancers affecting adult women. Symptoms for breast cancer may include swelling of all or part of a breast, skin irritation, thickening of the nipple or breast skin and abnormal nipple discharge. Symptoms for ovarian cancer may include abdominal bloating, indigestion, increased urge to urinate, constipation and menstrual irregularities.
